Cheng Zu
Impact in
- Oncology top 10%
- CAR-T cell therapy research
- Biochemistry top 10%
- Eicosanoids and Hypertension Pharmacology
Papers in
- Oncology 12
- CAR-T cell therapy research 11
- Cancer Immunotherapy and Biomarkers 2
-
- Eicosanoids and Hypertension Pharmacology 3
- Co-authors
- He Huang (8 shared papers)Chen‐Yu Zhang (4 shared papers)Yongxian Hu (9 shared papers)Hui‐Hui Yang (4 shared papers)Yong Zhou (4 shared papers)Cha‐Xiang Guan (3 shared papers)Jia‐Xi Duan (3 shared papers)Xinxin Guan (3 shared papers)
- Journals
- Bone Marrow Transplantation (1 paper)Journal of Cellular Physiology (1 paper)Acta Biochimica et Biophysica Sinica (1 paper)EClinicalMedicine (1 paper)npj Vaccines (1 paper)
- Partner nations
- ChinaUnited StatesGermany
In The Last Decade
Cheng Zu
23 papers receiving 527 citations
Cheng Zu's Hit Papers
Peers
Comparison fields: 5 of 62
- Oncology 317
- Biochemistry 51
- Immunology 98
- Hematology 41
- Genetics 95
Countries citing papers authored by Cheng Zu
This map shows the geographic impact of Cheng Zu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Cheng Zu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Cheng Zu more than expected).
Fields of papers citing papers by Cheng Zu
This network shows the impact of papers produced by Cheng Zu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Cheng Zu. The network helps show where Cheng Zu may publish in the future.
Co-authors
The 25 scholars most cited alongside Cheng Zu, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 24 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Genetically modified CD7-targeting allogeneic CAR-T cell therapy with enhanced efficacy for relapsed/refractory CD7-positive hematological malignancies: a phase I clinical study Hit paper breakdown → | 2022 | 163 |
| 2 | 2024 | 80 | |
| 3 | 2020 | 49 | |
| 4 | 2020 | 43 | |
| 5 | 2023 | 43 | |
| 6 | 2021 | 21 | |
| 7 | 2023 | 19 | |
| 8 | 2023 | 18 | |
| 9 | 2022 | 17 | |
| 10 | 2023 | 17 | |
| 11 | 2022 | 14 | |
| 12 | 2022 | 11 | |
| 13 | 2025 | 10 | |
| 14 | 2021 | 8 | |
| 15 | 2022 | 6 | |
| 16 | 2023 | 5 | |
| 17 | 2022 | 3 | |
| 18 | 2022 | 2 | |
| 19 | 2023 | 2 | |
| 20 | 2024 | 1 |
About Cheng Zu
Cheng Zu is a scholar working on Oncology, Biochemistry, Immunology, Molecular Biology and Hematology, having authored 24 papers that have together received 535 indexed citations. Recurring topics across this work include CAR-T cell therapy research (11 papers), Viral Infectious Diseases and Gene Expression in Insects (3 papers), Eicosanoids and Hypertension Pharmacology (3 papers), Methemoglobinemia and Tumor Lysis Syndrome (2 papers), Immunotherapy and Immune Responses (2 papers), Heme Oxygenase-1 and Carbon Monoxide (2 papers), Virus-based gene therapy research (2 papers) and Cancer Immunotherapy and Biomarkers (2 papers). The work is most often cited by research in Oncology (317 citations), Biochemistry (51 citations), Immunology (98 citations), Hematology (41 citations) and Genetics (95 citations). Cheng Zu has collaborated with scholars based in China, United States and Germany. Frequent co-authors include He Huang, Chen‐Yu Zhang, Yongxian Hu, Hui‐Hui Yang, Yong Zhou, Cha‐Xiang Guan, Jia‐Xi Duan, Xinxin Guan, Jiazhen Cui and Guoqing Wei. Their work appears in journals such as Bone Marrow Transplantation, Journal of Cellular Physiology, Acta Biochimica et Biophysica Sinica, EClinicalMedicine and npj Vaccines.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.